T1	Participants 54 118	patients with hormone receptor-positive metastatic breast cancer
T2	Participants 436 640	Patients with newly metastatic disease or recurred after adjuvant tamoxifen (stratum 1), or recurred during/after adjuvant aromatase inhibitor (AI) or after failed first-line AI (stratum 2), were eligible
